![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/eupraxia-pharmaceuticals-reports-second-quarter-2024-financial-results-302217162.html
https://www.prnewswire.com/news-releases/eupraxia-pharmaceuticals-announces-new-c12-million-convertible-debt-facility-302213214.html
https://www.prnewswire.com/news-releases/eupraxia-pharmaceuticals-to-present-at-controlled-release-society-2024-annual-meeting-and-expo-302190224.html
https://www.prnewswire.com/news-releases/eupraxia-pharmaceuticals-ceo-dr-james-helliwell-to-participate-in-webinar-event-exploring-the-rapid-rise-of-osteoarthritis-on-july-9-2024-302189221.html
https://www.prnewswire.com/news-releases/eupraxia-pharmaceuticals-announces-voting-results-from-annual-general-and-special-meeting-of-shareholders-302166561.html
https://www.prnewswire.com/news-releases/eupraxia-pharmaceuticals-announces-expansion-of-resolve-phase-1b2a-trial-of-ep-104gi-for-treatment-of-eosinophilic-esophagitis-302154726.html
https://www.prnewswire.com/news-releases/eupraxia-pharmaceuticals-to-host-virtual-kol-event-on-ep-104gi-clinical-development-program-for-eosinophilic-esophagitis-eoe-on-may-29-2024-302152284.html
https://www.prnewswire.com/news-releases/eupraxia-pharmaceuticals-announces-new-positive-data-from-resolve-phase-1b2a-trial-of-ep-104gi-for-treatment-of-eosinophilic-esophagitis-302151998.html
https://www.prnewswire.com/news-releases/eupraxia-pharmaceuticals-to-present-initial-results-from-ongoing-phase-1b-study-of-ep-104gi-for-the-treatment-of-eosinophilic-esophagitis-at-upcoming-digestive-disease-week-annual-meeting-2024-302144334.html
https://www.prnewswire.com/news-releases/eupraxia-pharmaceuticals-reports-first-quarter-2024-financial-results-and-provides-corporate-update-302140476.html